HomeAI · summaries
Storia in 2 fonti
Bristol Myers Squibb Moves Closer to New Multiple Myeloma Treatment - Bristol-Myers Squibb (NYSE:BMY)
FDA accepts Bristol Myers Squibb's mezigdomide NDA for relapsed multiple myeloma, with a PDUFA decision due May 13, 2027.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or…
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
- ·
benzinga.com
Bristol Myers Squibb Moves Closer to New Multiple Myeloma Treatment - Bristol-Myers Squibb (NYSE:BMY)
FDA accepts Bristol Myers Squibb's mezigdomide NDA for relapsed multiple myeloma, with a PDUFA decision due May 13, 2027.